AN ACT TO AUTOMATICALLY SCHEDULE, ON THE STATE SCHEDULES OF CONTROLLED SUBSTANCES, ANY PHARMACEUTICAL COMPOSITION CRYSTALLINE POLYMORPH PSILOCYBIN THAT IS APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION AND SCHEDULED BY THE UNITED STATES DRUG ENFORCEMENT ADMINISTRATION; TO PROVIDE THAT THE AUTOMATIC SCHEDULING SHALL BE EFFECTIVE FOR A CERTAIN TIME PERIOD; TO AMEND SECTION 41-29-111, MISSISSIPPI CODE OF 1972, TO DELETE OUTDATED LANGUAGE RELATED TO COVID-19; AND FOR RELATED PURPOSES.
Summary
SB 2056 creates an automatic state scheduling mechanism for a narrow category of psilocybin products: any pharmaceutical composition of crystalline polymorph psilocybin that is approved by the U.S. Food and Drug Administration and then scheduled by the U.S. Drug Enforcement Administration would be placed on the corresponding Mississippi controlled-substance schedule without waiting for a separate state bill. The automatic scheduling would apply immediately upon federal scheduling and remain in effect until the Legislature changes the state schedule or until the next regular legislative session ends, whichever comes first.
The bill also amends Mississippi Code Section 41-29-111, which governs how controlled substances are recommended and scheduled, to remove outdated COVID-19-related language. The existing framework requiring the State Board of Health to consider abuse potential, scientific evidence, public health risk, and related factors remains in place, but the bill adds a specific automatic-trigger rule tied to federal action for the psilocybin product described in the bill.
Impact
The bill would affect Mississippi’s Uniform Controlled Substances Law by linking state scheduling of a specific FDA-approved psilocybin pharmaceutical to federal DEA scheduling, temporarily bypassing the usual state recommendation-and-legislation process for that substance. If triggered, the substance would be subject to the penalties and enforcement provisions associated with the applicable state schedule in Sections 41-29-113 through 41-29-121. It also cleans up Section 41-29-111 by deleting obsolete COVID-19 scheduling language, while leaving the broader state controlled-substances review structure intact.
Sentiment
The bill appears to have been broadly supported, passing the Senate 52-0 and the House 119-0. The unanimous votes suggest little overt opposition in the recorded legislative history, and there were no committee transcript excerpts indicating significant debate. Overall, the sentiment reflected in the voting history is strongly favorable and largely procedural rather than contentious.
Contention
No major points of contention are evident in the available record. The main policy issue implicit in the bill is whether Mississippi should automatically follow federal scheduling for a specific psilocybin pharmaceutical rather than requiring separate state action, but the unanimous votes indicate that any concerns were not enough to generate recorded opposition. The only other substantive change—removing outdated COVID-19 scheduling language—appears noncontroversial.